# Intravitreal Bevacizumab for Idiopathic Macular Telangiectasia

> **NCT00451763** · PHASE3 · COMPLETED · sponsor: **University of Sao Paulo** · enrollment: 31 (actual)

## Conditions studied

- Retina
- Telangiectasis

## Interventions

- **DRUG:** Intravitreal Injection of Bevacizumab (1.25 mg/0.05ml)

## Key facts

- **NCT ID:** NCT00451763
- **Lead sponsor:** University of Sao Paulo
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2006-12
- **Final completion:** 2007-12
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2008-07-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00451763

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00451763, "Intravitreal Bevacizumab for Idiopathic Macular Telangiectasia". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00451763. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*